Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Intrahepatic cholangiocarcinoma: circulating tumor DNA as a novel translational clinicopathologic and molecular biomarker

FY 2020-21

Summary
Intrahepatic cholangiocarcinoma (iCCA) is the second most common cause of primary liver cancer with a dismal survival rate of 10% over five years. The main challenge in delivering the optimal treatment lies in: 1) obtaining gene mutational information of the iCCA tumor 2) reliably detecting cancer recurrence after surgical cure. Harvesting circulating tumor DNA (ctDNA) from the bloodstream and studying them might provide a solution to these issues. ctDNA or so-called ""liquid biopsies"" are DNA fragments released in the bloodstream from the tumor cells undergoing programmed cell death. ctDNA is hypothesized to carry the same genetic altercations of the main tumor. Potential ctDNA application includes: 1) monitoring for cancer recurrence 2) delivering tailored therapies based on mutations discovered 3) serving as a biomarker to detect cancer recurrence after surgery. However, there is very few data available for patients with iCCA diagnosis. One iCCA study highlights up to 92% concordance rate between the mutations of the cancer tissue and ctDNA after analyzing 15 cancer genes of interest. As this study only includes patients with metastatic cancer, the utility of ctDNA in patients undergoing curative surgery remains unknown. Hence, this research proposal seeks to study adult patients who undergo curative-intent surgery for iCCA by: 1) assess whether the mutations of peri-operative (before and after surgery) ctDNA in the bloodstream matches to those of the resected primary tumor 2) assess whether peri-operative ctDNA concentration in the bloodstream is a predictor of recurrence and overall survival for resected iCCA. We hypothesize that the bloodstream ctDNA is a surrogate for mutations in the main tumor and associated with natural history in resected iCCA.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
449827
Name
Choi Woo Jin
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Intrahepatic cholangiocarcinoma: circulating tumor DNA as a novel translational clinicopathologic and molecular biomarker
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bile Duct Cancer; Ctdna; Fgfr2; Idh1; Intrahepatic Cholangiocarcinoma; Liquid Biopsy; Mutations; Resection; Sequencing; Surgery
Abstract
Intrahepatic cholangiocarcinoma (iCCA) is the second most common cause of primary liver cancer with a dismal survival rate of 10% over five years. The main challenge in delivering the optimal treatment lies in: 1) obtaining gene mutational information of the iCCA tumor 2) reliably detecting cancer recurrence after surgical cure. Harvesting circulating tumor DNA (ctDNA) from the bloodstream and studying them might provide a solution to these issues. ctDNA or so-called ""liquid biopsies"" are DNA fragments released in the bloodstream from the tumor cells undergoing programmed cell death. ctDNA is hypothesized to carry the same genetic altercations of the main tumor. Potential ctDNA application includes: 1) monitoring for cancer recurrence 2) delivering tailored therapies based on mutations discovered 3) serving as a biomarker to detect cancer recurrence after surgery. However, there is very few data available for patients with iCCA diagnosis. One iCCA study highlights up to 92% concordance rate between the mutations of the cancer tissue and ctDNA after analyzing 15 cancer genes of interest. As this study only includes patients with metastatic cancer, the utility of ctDNA in patients undergoing curative surgery remains unknown. Hence, this research proposal seeks to study adult patients who undergo curative-intent surgery for iCCA by: 1) assess whether the mutations of peri-operative (before and after surgery) ctDNA in the bloodstream matches to those of the resected primary tumor 2) assess whether peri-operative ctDNA concentration in the bloodstream is a predictor of recurrence and overall survival for resected iCCA. We hypothesize that the bloodstream ctDNA is a surrogate for mutations in the main tumor and associated with natural history in resected iCCA.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Choi, Woo Jin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~